Frankfurt
31.08.26 | 08:05
0,037 Euro
-25,20 % -0,012
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 2CUREX Aktie jetzt für 0€ handeln | |||||
| 01.09. | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 01.09.2026 | 707 | Xetra Newsboard | The following instruments on Boerse Frankfurt do have their last trading day on 01.09.2026Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 01.09.2026ISIN NameAU0000111247 WA... ► Artikel lesen | |
| 01.09. | XFRA 2QE: AUSSETZUNG/SUSPENSION | 187 | Xetra Newsboard | DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTIL2CUREX AB SEK-,10... ► Artikel lesen | |
| 27.08. | 2cureX AB: 2cureX AB (publ) publishes Interim Report for the First Half of 2026 | 423 | GlobeNewswire (Europe) | 2cureX AB ("2cureX" or the "Company") hereby publishes its interim report for the first half of 2026 (1 January - 30 June 2026).
The first half of 2026 was characterised by strengthened financing, active... ► Artikel lesen | |
| 18.08. | 2cureX AB: Nasdaq decides to delist 2cureX AB | 435 | GlobeNewswire (Europe) | 2cureX AB (the "Company") was informed on 17 August 2026 that Nasdaq Stockholm AB ("Nasdaq") has decided to delist the Company's shares from Nasdaq First North Growth Market. The last day of trading... ► Artikel lesen | |
| 17.08. | 2cureX AB - Removal from trading on Nasdaq First North Growth Market | 466 | GlobeNewswire | According to item 2.3.7 of the Nasdaq First North Growth Market Rulebook, an issuer shall be able to demonstrate ongoing business operations.
According to item 8.2.7 of the Nasdaq First North... ► Artikel lesen | |
| 06.07. | The observation status for 2cureX is updated | 530 | GlobeNewswire | On February 27, 2026, the shares in Insplorion AB (the "Company") were given observation status with reference to uncertainty in respect of the issuer's financial position.
On July 6, 2026... ► Artikel lesen | |
| 06.07. | 2cureX AB: 2cureX AB accelerates reintegration of operating business into the listed company | 431 | GlobeNewswire (Europe) | 2cureX AB (publ) ("2cureX" or the "Company") today announces that it has submitted comprehensive documentation to Nasdaq Stockholm demonstrating the Company's ongoing commercial activities, operational... ► Artikel lesen | |
| 25.06. | 2curex AB: Communiqué From The Annual General Meeting On Thursday 25 June 2026 In 2curex Ab | 288 | GlobeNewswire (Europe) | N.B. The English text is an unofficial translation. Today, 25 June 2026, the Annual General Meeting (the "AGM") of 2cureX AB, reg. no. 559128-0077, was held. Below is a summary of the resolutions passed.... ► Artikel lesen | |
| 20.05. | 2cureX AB: 2cureX AB Expands Functional Precision Medicine Infrastructure Through Strategic Collaboration with StoreMyTumor | 304 | GlobeNewswire (Europe) | 2cureX AB today announces the signing of a strategic services and collaboration agreement with StoreMyTumor, a US-based oncology logistics and tumour preservation platform operating under AAA Health... ► Artikel lesen | |
| 22.04. | 2cureX AB: 2cureX AB completes oversubscribed directed issue | 297 | GlobeNewswire (Europe) | 2cureX AB ("2cureX" or the "Company") today announces that it has successfully completed an oversubscribed directed share issue of 6,800,000 shares to a select group of international investors (the... ► Artikel lesen | |
| 27.02. | 2cureX AB receives observation status | 301 | GlobeNewswire | Yesterday, February 26, 2026, 2cureX AB (the "Company") disclosed its annual financial statement release for 2025 with information on the Company's financial situation.
According to item 6.3.1... ► Artikel lesen | |
| 26.02. | 2cureX AB: 2cureX AB (publ) publishes Interim Report for the Second Half of 2025 | 341 | GlobeNewswire (Europe) | 2cureX AB ("2cureX" or the "Company") hereby publishes its interim report for the second half of 2025 (July 1 - December 31, 2025).
The second half of 2025 has been characterised by continued execution... ► Artikel lesen |
12 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| MEDIGENE | 0,005 | 0,00 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 30.06.2026 | The following instruments on Boerse Frankfurt do have their last trading day on 30.06.2026Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 30.06.2026ISIN NameBE0003593044 COFINIMMOCA8765111064 TASEKO... ► Artikel lesen | |
| EPIGENOMICS | 0,880 | -3,30 % | PTA-AFR: Epigenomics AG: Vorabbekanntmachung über die Veröffentlichung von Finanzberichten gemäß §§ 114-117 WpHG | DJ PTA-AFR: Epigenomics AG: Vorabbekanntmachung über die Veröffentlichung von Finanzberichten gemäß §§ 114-117 WpHG
Vorabbekanntmachung Finanzberichte gemäß ---- 114-117 WpHG
Epigenomics... ► Artikel lesen | |
| BIOFRONTERA | 3,120 | +6,85 % | Biofrontera AG: FDA-Erfolg - diese Frage bleibt offen | ||
| NANOREPRO | 1,780 | +2,30 % | Original-Research: NanoRepro AG (von NuWays AG): KAUFEN | Original-Research: NanoRepro AG - von NuWays AG
05.10.2026 / 09:00 CET/CEST
Veröffentlichung einer Research, übermittelt durch EQS News - ein Service der EQS Group.
Für den Inhalt der Mitteilung... ► Artikel lesen | |
| BIOXXMED | 1,050 | 0,00 % | PTA-News: bioXXmed AG: Einladung zur Hauptversammlung | DJ PTA-News: bioXXmed AG: Einladung zur Hauptversammlung
Unternehmensmitteilung für den Kapitalmarkt
bioXXmed AG: Einladung zur Hauptversammlung
Heidelberg (pta000/20.07.2026/15:45... ► Artikel lesen | |
| OCUGEN | 0,851 | -0,23 % | Ocugen Appoints Industry Executive Jolanda Crombach General Manager of European Affiliate | European Affiliate, based in Amsterdam, to support upcoming marketing authorization submissions, OCU410 Phase 3 development program, and potential commercialization in Europe MALVERN, Pa., Oct. 06... ► Artikel lesen | |
| CLINUVEL | 4,945 | -1,22 % | Telix vs Clinuvel Pharmaceuticals: Which ASX healthcare share deserves your next $1,000 of investment capital? | ||
| SANGAMO THERAPEUTICS | 0,126 | -100,00 % | NSE - SANGAMO THERAPEUTICS, INC - 25, Notification of the removal from listing and registration of matured, redeemed or retired securities | ||
| COSCIENS BIOPHARMA | 5,530 | -2,12 % | XFRA ET80: WIEDERAUFNAHME/RESUMPTION | FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE:INSTRUMENT NAME... ► Artikel lesen | |
| SCORPIUS | - | - | Scorpius Holdings, Inc. - 8-K, Current Report | ||
| EDITAS MEDICINE | 2,590 | 0,00 % | Editas Medicine, Inc.: Editas Medicine Receives Approval to Initiate First-In-Human Clinical Trial of EDIT-401 in Patients with Hyperlipidemia | Phase 1/2 clinical trial of EDIT-401 cleared to initiate dosing in patients who require additional LDL-C lowering Company remains on track to begin patient dosing this year and report initial safety... ► Artikel lesen | |
| SAREPTA THERAPEUTICS | 15,920 | -0,13 % | Jim Cramer Explains His Hesitation Over Sarepta (SRPT) Therapeutics | ||
| IBIO | 0,839 | +6,95 % | iBio, Inc.: iBio Reports Fiscal Year 2026 Financial Results and Provides Corporate Update | SAN DIEGO, Aug. 28, 2026 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ: IBIO), a clinical-stage biotechnology company developing long-acting antibody therapeutics for obesity, cardiometabolic and cardiopulmonary... ► Artikel lesen | |
| ASEP MEDICAL | 0,050 | 0,00 % | XFRA JJ80: AUSSETZUNG/SUSPENSION | DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILASEP MEDICAL HOLDINGS... ► Artikel lesen | |
| MYRIAD GENETICS | 3,844 | 0,00 % | Myriad Genetics, Inc.: Myriad Genetics and SOPHiA GENETICS Announce New Collaboration to Advance Prostate Genomic Instability Score Technology | SALT LAKE CITY and BOSTON, Oct. 08, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine and SOPHiA GENETICS (NASDAQ: SOPH)... ► Artikel lesen |
Das Unternehmen 2CUREX AB kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell -25,20 % bei einem Aktienkurs von 0,037 Euro. Die Dividendendrendite beträgt aktuell 0,00 % (berechnet anhand der Ausschüttung von 0,00 Euro in den letzten 12 Monaten).
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu 2CUREX AB finden Sie auf Wallstreet Online.